Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-κB

被引:161
作者
Loiarro, M
Sette, C
Gallo, G
Ciacci, A
Fantò, N
Mastroianni, D
Carminati, P
Ruggiero, V
机构
[1] Sigma Tau Ind Farmaceut Riunite SpA, Dept Immunol, I-00040 Pomezia, RM, Italy
[2] Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00173 Rome, Italy
[3] Tecnogen SCpA, I-81015 Piana Di Monte Verna, CE, Italy
关键词
D O I
10.1074/jbc.C400613200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myeloid differentiation factor 88 (MyD88) plays a crucial role in the signaling pathways triggered by interleukin (IL)-1 and Toll-like receptors in several steps of innate host defense. A crucial event in this signaling pathway is represented by dimerization of MyD88, which allows the recruitment of downstream kinases like IRAK-1 and IRAK-4. Herein, we have investigated the function of the Toll/IL-1 receptor (TIR) domain in MyD88 homodimerization in cell-free and in vitro experimental settings by using epta-peptides that mimic the BB-loop region of the conserved TIR domain of different proteins. By using a pull-down assay with purified glutathione S-transferase-MyD88 TIR or co-immunoprecipitation experiments, we found that epta-peptides derived from the TIR domain of MyD88 and IL-18R are the most effective in inhibiting homodimerization with either the isolated TIR or full-length MyD88. Moreover, we demonstrated that a cell permeable analog of MyD88 epta-peptide inhibits homodimerization of MyD88 TIR domains in an in vitro cell system and significantly reduces IL-1 signaling, as assayed by activation of the downstream transcription factor NF-kappa B. Our results indicate that the BB-loop in TIR domain of MyD88 is a good target for specific inhibition of MyD88-mediated signaling in vivo.
引用
收藏
页码:15809 / 15814
页数:6
相关论文
共 29 条
[1]   Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function [J].
Adachi, O ;
Kawai, T ;
Takeda, K ;
Matsumoto, M ;
Tsutsui, H ;
Sakagami, M ;
Nakanishi, K ;
Akira, S .
IMMUNITY, 1998, 9 (01) :143-150
[2]   Toll-like receptor signaling [J].
Akira, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (40) :38105-38108
[3]   Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[4]   A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses [J].
Bartfai, T ;
Behrens, MM ;
Gaidarova, S ;
Pemberton, J ;
Shivanyuk, A ;
Rebek, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (13) :7971-7976
[5]   Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain [J].
Baud, V ;
Liu, ZG ;
Bennett, B ;
Suzuki, N ;
Xia, Y ;
Karin, M .
GENES & DEVELOPMENT, 1999, 13 (10) :1297-1308
[6]   Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways [J].
Björkbacka, H ;
Kunjathoor, VV ;
Moore, KJ ;
Koehn, S ;
Ordija, CM ;
Lee, MA ;
Means, T ;
Halmen, K ;
Luster, AD ;
Golenbock, DT ;
Freeman, MW .
NATURE MEDICINE, 2004, 10 (04) :416-421
[7]  
Bodanszky M., 1993, PRINCIPLES PEPTIDE S, V2nd
[8]   MyD88, an adapter protein involved in interleukin-1 signaling [J].
Burns, K ;
Martinon, F ;
Esslinger, C ;
Pahl, H ;
Schneider, P ;
Bodmer, JL ;
Di Marco, F ;
French, L ;
Tschopp, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (20) :12203-12209
[9]   Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling [J].
Choe, JY ;
Crain, B ;
Wu, SR ;
Corr, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (04) :537-542
[10]   Structural complementarity of Toll/interleukin-1 receptor domains in toll-like receptors and the adaptors Mal and MyD88 [J].
Dunne, A ;
Ejdebäck, M ;
Ludidi, PL ;
O'Neill, LAJ ;
Gay, NJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (42) :41443-41451